

Systemic Juvenile Idiopathic Arthritis Market - 2022-2030

<https://marketpublishers.com/r/S985E219A269EN.html>

Date: December 2025

Pages: 243

Price: US\$ 2,999.00 (Single User License)

ID: S985E219A269EN

Abstracts

The Systemic Juvenile Idiopathic Arthritis Market was valued at US\$ 0.87 billion in 2022 and is anticipated to reach US\$ 1.19 billion by 2030, at a CAGR of 0.041 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Systemic Juvenile Idiopathic Arthritis Market.

This report delivers a comprehensive overview of the Systemic Juvenile Idiopathic Arthritis Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Systemic Juvenile Idiopathic Arthritis Market. The Systemic Juvenile Idiopathic Arthritis Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2022–2030.

Systemic Juvenile Idiopathic Arthritis Market Scope:

By Treatment Type

Drug Treatment

Biologics

Other

By Route of Administration

Oral

Injectables

Other

By Age Group

Infants

Childrens

Adolescents

By End-User

Hospitals

Specialty Clinics

Academic Research Centers

Others

Key Players

Novartis AG

Hoffmann-La Roche Ltd

Takeda Pharmaceutical Company Limited

Bristol – Myers Squibb Company

Cadila Healthcare Ltd.

Genetech, Inc.

LATAM Pharma

Alteogen Inc.

Johnson & Johnson

Momenta Pharmaceuticals, Inc.

Major Highlights

This report delivers a comprehensive overview of the Systemic Juvenile Idiopathic Arthritis Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Systemic Juvenile Idiopathic Arthritis Market. The Systemic Juvenile Idiopathic Arthritis Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2022–2030.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. METHODOLOGY AND SCOPE

- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report

2. DEFINITION AND OVERVIEW

3. EXECUTIVE SUMMARY

- 3.1. Snippet by Treatment Type
- 3.2. Snippet by Route of Administration
- 3.3. Snippet by Age Group
- 3.4. Snippet by End-User
- 3.5. Snippet by Region

4. DYNAMICS

- 4.1. Impacting Factors
 - 4.1.1. Drivers
 - 4.1.1.1. Increasing Product Approvals and Positive Research Outcomes
 - 4.1.1.2. Increasing Efforts from Distinct Associations
 - 4.1.2. Restraints
 - 4.1.2.1. High Treatment Cost of Systemic Juvenile Idiopathic Arthritis
 - 4.1.2.2. Low Prevalence of the Disorder
 - 4.1.3. Opportunity
 - 4.1.4. Impact Analysis

5. INDUSTRY ANALYSIS

- 5.1. Porter's Five Force Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Regulatory Analysis
- 5.5. Patent Analysis
- 5.6. Technology Trend
- 5.7. End-User Trend
- 5.8. SWOT Analysis

5.9. DMI Opinion

6. COVID-19 ANALYSIS

6.1. Analysis of COVID-19

6.1.1. Scenario Before COVID

6.1.2. Scenario During COVID

6.1.3. Scenario Post COVID

6.2. Pricing Dynamics Amid COVID-19

6.3. Demand-Supply Spectrum

6.4. Government Initiatives Related to the Market During Pandemic

6.5. Manufacturers Strategic Initiatives

6.6. Conclusion

7. BY TREATMENT TYPE

7.1. Introduction

7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type

7.1.2. Market Attractiveness Index, By Treatment Type

7.2. Drug Treatment*

7.2.1. Introduction

7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

7.2.3. Anti-inflammatories (NSAIDS)

7.2.4. Tumor Necrosis Factor (TNF) Blockers

7.2.5. Muscle Relaxants

7.2.6. Immune Suppressants Drugs

7.2.7. Disease Modifying Antirheumatic Drugs

7.2.8. Others

7.3. Biologics

7.4. Other

8. BY ROUTE OF ADMINISTRATION

8.1. Introduction

8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration

8.1.2. Market Attractiveness Index, By Route of Administration

8.2. Oral*

8.2.1. Introduction

- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Injectables
- 8.4. Other

9. BY AGE GROUP

- 9.1. Introduction
 - 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
 - 9.1.2. Market Attractiveness Index, By Age Group
- 9.2. Infants*
 - 9.2.1. Introduction
 - 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. Childrens
- 9.4. Adolescents

10. BY END-USER

- 10.1. Introduction
 - 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
 - 10.1.2. Market Attractiveness Index, By End-User
- 10.2. Hospitals*
 - 10.2.1. Introduction
 - 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 10.3. Specialty Clinics
- 10.4. Academic Research Centers
- 10.5. Others

11. BY REGION

- 11.1. Introduction
 - 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
 - 11.1.2. Market Attractiveness Index, By Region
- 11.2. North America
 - 11.2.1. Introduction
 - 11.2.2. Key Region-Specific Dynamics
 - 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
 - 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
 - 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group

- 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 11.2.7.1. U.S.
 - 11.2.7.2. Canada
 - 11.2.7.3. Mexico
- 11.3. Europe
 - 11.3.1. Introduction
 - 11.3.2. Key Region-Specific Dynamics
 - 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
 - 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
 - 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
 - 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
 - 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 11.3.7.1. Germany
 - 11.3.7.2. UK
 - 11.3.7.3. France
 - 11.3.7.4. Italy
 - 11.3.7.5. Spain
 - 11.3.7.6. Rest of Europe
- 11.4. South America
 - 11.4.1. Introduction
 - 11.4.2. Key Region-Specific Dynamics
 - 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
 - 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
 - 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
 - 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
 - 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 11.4.7.1. Brazil
 - 11.4.7.2. Argentina
 - 11.4.7.3. Rest of South America
- 11.5. Asia-Pacific
 - 11.5.1. Introduction
 - 11.5.2. Key Region-Specific Dynamics
 - 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
 - 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
 - 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group

- 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 11.5.7.1. China
 - 11.5.7.2. India
 - 11.5.7.3. Japan
 - 11.5.7.4. Australia
 - 11.5.7.5. Rest of Asia-Pacific
- 11.6. Middle East and Africa
 - 11.6.1. Introduction
 - 11.6.2. Key Region-Specific Dynamics
 - 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
 - 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
 - 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
 - 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. COMPETITIVE LANDSCAPE

- 12.1. Competitive Scenario
- 12.2. Market Positioning/Share Analysis
- 12.3. Mergers and Acquisitions Analysis

13. COMPANY PROFILES

- 13.1. Novartis AG*
 - 13.1.1. Company Overview
 - 13.1.2. Product Portfolio and Description
 - 13.1.3. Financial Overview
 - 13.1.4. Key Developments
- 13.2. Hoffmann-La Roche Ltd
- 13.3. Takeda Pharmaceutical Company Limited
- 13.4. Bristol – Myers Squibb Company
- 13.5. Cadila Healthcare Ltd.
- 13.6. Genetech, Inc.
- 13.7. LATAM Pharma
- 13.8. Alteogen Inc.
- 13.9. Johnson & Johnson
- 13.10. Momenta Pharmaceuticals, Inc. (*LIST NOT EXHAUSTIVE)

14. APPENDIX

14.1. About Us and Services

14.2. Contact Us

I would like to order

Product name: Systemic Juvenile Idiopathic Arthritis Market - 2022-2030

Product link: <https://marketpublishers.com/r/S985E219A269EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S985E219A269EN.html>